The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa

Journal of Bacteriology

Volumn 191, Issue 22, 2009, Pages 6968-6974

  Castañeda García, Alfredo ^a   Rodríguez Rojas, Alexandro ^a   Guelfo, Javier R ^a   Blázquez, Jesús ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; GLYCEROL 3 PHOSPHATE PERMEASE; GLYCEROPHOSPHATE; PERMEASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CARBON SOURCE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE INACTIVATION; GENE INSERTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOFILMS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; GENETIC COMPLEMENTATION TEST; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA;

ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA;

EID: 70350457941     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.00748-09     Document Type: Article

References (44)

1. Alper, M. D., and B. N. Ames. 1978. Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J. Bacteriol. 133:149-157.
2. Ambudkar, S. V., V. Anantharam, and P. C. Maloney. 1990. UhpT, the sugar phosphate antiporter of Escherichia coli, functions as a monomer. J. Biol. Chem. 265:12287-12292.
3. Baba, T., T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K. A. Datsenko, M. Tomita, B. L. Wanner, and H. Mori. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2:2006-2008.
4. Bernat, B. A., L. T. Laughlin, and R. N. Armstrong. 1997. Fosfomycin resistance protein (FosA) is a manganese metalloglutathione transferase related to glyoxalase I and the extradiol dioxygenases. Biochemistry 36:3050-3055.
5. Ciofu, O., B. Giwercman, S. S. Pedersen, and N. Hoiby. 1994. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 102:674-680.
6. Chin, N. X., N. M. Neu, and H. C. Neu. 1986. Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli. Drugs Exp. Clin. Res. 12:943-947.
7. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. 7th ed. CLSI, Wayne, PA.
8. Elvin, C. M., C. M. Hardy, and H. Rosenberg. 1985. Pi exchange mediated by the GlpT-dependent sn-glycerol-3-phosphate transport system in Escherichia coli. J. Bacteriol. 161:1054-1058.
9. Falagas, M. E., A. C. Kastoris, D. E. Karageorgopoulos, and P. I. Rafailidis. 2009. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 34:111-120.
10. Hardisson, C., and J. Llaneza. 1977. The action of fosfomycin on the growth of Pseudomonas aeruginosa. Chemotherapy 23(Suppl. 1):37-44.
11. Huang, Y., M. J. Lemieux, J. Song, M. Auer, and D. N. Wang. 2003. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301:616-620.
12. Kahan, F. M., J. S. Kahan, P. J. Cassidy, and H. Kropp. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. 235:364-386.
13. Kahlmeter, G. 2000. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - interim report. J. Antimicrob. Chemother. 46(Suppl. 1):15-65.
14. Kiewitz, C., and B. Tummler. 2000. Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J. Bacteriol. 182:3125-3135.
15. Kovach, M. E., P. H. Elzer, D. S. Hill, G. T. Robertson, M. A. Farris, R. M. Roop, Jr., and K. M. Peterson. 1995. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166:175-176.
16. Lemieux, M. J., Y. Huang, and D. N. Wang. 2004. Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation. Res. Microbiol. 155:623-629.
17. Lemieux, M. J., Y. Huang, and D. N. Wang. 2004. The structural basis of substrate translocation by the Escherichia coli glycerol-3-phosphate transporter: a member of the major facilitator superfamily. Curr. Opin. Struct. Biol. 14:405-412.
18. Liberati, N. T., J. M. Urbach, S. Miyata, D. G. Lee, E. Drenkard, G. Wu, J. Villanueva, T. Wei, and F. M. Ausubel. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc. Natl. Acad. Sci. USA 103:2833-2838.
19. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
20. Maciá, M. D., D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.
21. Maciá, M. D., N. Borrell, J. L. Perez, and A. Oliver. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob. Agents Chemother. 48:2665-2672.
22. Mandsberg, L. F., O. Ciofu, N. Kirkby, L. E. Christiansen, H. E. Poulsen, and N. Hoiby. 2009. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob. Agents Chemother. 53:2483-2491.
23. Merkel, T. J., J. L. Dahl, R. H. Ebright, and R. J. Kadner. 1995. Transcription activation at the Escherichia coli uhpT promoter by the catabolite gene activator protein. J. Bacteriol. 177:1712-1718.
24. Mirakhur, A., M. J. Gallagher, M. J. Ledson, C. A. Hart, and M. J. Walshaw. 2003. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2:19-24.
25. Moya, B., A. Dotsch, C. Juan, J. Blazquez, L. Zamorano, S. Haussler, and A. Oliver. 2009. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 5:e1000353.
26. Nilsson, A. I., O. G. Berg, O. Aspevall, G. Kahlmeter, and D. I. Andersson. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858.
27. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364.
28. Okazaki, M., K. Suzuki, N. Asano, K. Araki, N. Shukuya, T. Egami, Y. Higurashi, K. Morita, H. Uchimura, and T. Watanabe. 2002. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J. Infect. Chemother. 8:37-42.
29. Olay, T., A. Rodriguez, L. E. Oliver, M. V. Vicente, and M. C. Quecedo. 1978. Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies. J. Antimicrob. Chemother. 4:569-576.
30. Olekhnovich, I. N., J. L. Dahl, and R. J. Kadner. 1999. Separate contributions of UhpA and CAP to activation of transcription of the uhpT promoter of Escherichia coli. J. Mol. Biol. 292:973-986.
31. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
32. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blazquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
33. Patel, S. S., J. A. Balfour, and H. M. Bryson. 1997. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53:637-656.
34. Plasencia, V., N. Borrell, M. D. Macia, B. Moya, J. L. Perez, and A. Oliver. 2007. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob. Agents Chemother. 51:2574-2581.
35. Reeves, D. S. 1994. Fosfomycin trometamol. J. Antimicrob. Chemother. 34:853-858.
36. Rodríguez-Rojas, A., and J. Blazquez. 2009. The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection. J. Bacteriol. 191:844-850.
37. Saiman, L. 2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8:249-255.
38. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
39. Schweizer, H. P., and C. Po. 1996. Regulation of glycerol metabolism in Pseudomonas aeruginosa: characterization of the glpR repressor gene. J. Bacteriol. 178:5215-5221.
40. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, and M. V. Olson. 2000. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406:959-964.
41. Suárez, J. E., and M. C. Mendoza. 1991. Plasmid-encoded fosfomycin resistance. Antimicrob. Agents Chemother. 35:791-795.
42. Tessier, F., and C. Quentin. 1997. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 16:159-162. (Pubitemid 27135969)
43. Tsuruoka, T., A. Miyata, and Y. Yamada. 1978. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J. Antibiot. (Tokyo) 31:192-201. (Pubitemid 8326008)
44. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother. 42:953-955.